RxDoctor Payments Data

Mohd Boda, MD

Internal Medicine · Lees Summit, MONPI 1285673038

Payments from drug & device makers

$6,259in general payments, 2019–2025

Across 291 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Organogenesis Inc.$729
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$378
  • Lilly USA, LLC$356
  • Abbott$234
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$6,20599%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,259 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$128,402
Medicare patients
277
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide104$162,186
JardianceEmpagliflozin87$118,264
OzempicSemaglutide54$92,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$26,694
EliquisApixaban29$25,840
VraylarCariprazine Hcl12$17,339
TrulicityDulaglutide13$15,896
JanuviaSitagliptin Phosphate20$15,129
ArexvyRsvpref3 Antigen/As01e/Pf44$12,424
MyrbetriqMirabegron16$11,302
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$9,237
Rosuvastatin Calcium367$5,461
Atorvastatin Calcium267$3,689
Gabapentin133$3,467
Levemir FlexpenInsulin Detemir12$3,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$356$178,082117 claims
Boehringer IngelheimJardiance$137$118,26487 claims
Novo NordiskOzempic$1,066$92,08354 claims
GSKTrelegy Ellipta, Arexvy$179$39,11875 claims
PfizerEliquis$184$25,84029 claims
AbbVieVraylar$1,174$17,33912 claims
MerckJanuvia$93$15,12920 claims
Astellas Pharma US IncMyrbetriq$117$11,30216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →